Kornimate/medical-research-clean huggingface dataset:
elomia - digital mental health and well-being

Conditions: Symptoms of Depression and Anxiety; Perceived Stress

Summary: this study is testing the acceptability and efficacy of an ai enabled mental health chatbot (elomia) as a resource of college student wellness.

elomia is a generative ai program that can respond to text users type in with unique responses that are designed to address therapeutic targets like stress, anxiety, procrastination, feeling overwhelmed and so on. elomia was "trained" by real therapists with expertise in cognitive-behavioral therapy who responded to many different real people typing about their concerns. thus, elomia can suggest a number of different evidence based therapeutic strategies and can help the user process negative feelings, think through problems, plan solutions, and trouble shoot things that might get in the way of implementing those strategies. elomia's arsenal includes: * exercises for calming; * exercises for falling asleep; * grounding techniques; * exercises to reduce anxiety; * breathing exercises; * exercises to improve self-esteem. the algorithm determines the user's need for one or another type of help while communicating with the chatbot and suggests an exercise to ease their emotional state. elomia is not a substitute for professional care, and will detect when a person needs something more than a chatbot and will suggest connecting with other resources. more information about elomia can be found via this website: https://elomia.com/ the ultimate goal of this study is to explore whether a mental health chatbot is acceptable and can improve symptoms of depression, anxiety, stress, and promote general psychological well-being in college students. the investigators will compare elomia to a curated collection of digital wellness resources that are typically provided to students at our university.

Eligibility criteria:
inclusion criteria: * undergraduate student at the university of pennsylvania. * at least 18 years of age. exclusion criteria: \* severe depression or suicidality as indicated by beck depression inventory score of \>= 30, and/or a score of 2 or 3 on the item (the suicide item) of the beck depression inventory

Keywords: psychological wellbeing digital mental health artificial intelligence college students elomia
efficacy of probiotics for nsaid-induced enteropathy in arthritis patients

Conditions: Osteoarthritis

Summary: this study aimed to investigate the efficacy of probiotics as a preventive agent for nsaid-induced enteropathy. arthritis patients are randomly divided into probiotic and placebo groups, and the drug is administered for eight weeks. before and after drug administration, the patient's symptoms/degree of small bowel injuries on capsule endoscopy/microbiome composition and diversity were investigated.

background: due to aging, there are many long-term users of nsaids, increasing enteropathy. the prophylactic effect of misoprostol, which is currently used, has not been proven, and misoprostol's long-term compliance and safety remain questionable. rebamipide shows insignificant effects in both treatment and prophylaxis. probiotics have been reported to affect enteropathy in animal and human studies. however, there needs to be more verification studies, and there needs to be confirmatory studies on the importance of the microbiome in the small bowel. however, it is expected that there will be fewer complications and less patient resistance, resulting in higher drug compliance. purpose: to identify the efficacy of probiotics on nsaid-induced enteropathy in arthritis patients by capsule endoscopy and questionnaire, and to analysis the composition and diversity of the microbiome design: double-blinded randomized controlled, pilot study participant: patients diagnosed with osteoarthritis and starting nsaids methods: randomly administering probiotics or placebo for eight weeks and comparing "before and after administration" in arthritis patients 1. survey of patient symptoms for enteropathy 2. recovery of small bowel mucosal injuries in capsule endoscopy 3. analysis of the composition and diversity of the microbiome 4. adverse events outcome * primary outcome: to assess whether probiotics can reduce small bowel injuries caused by nsaids * secondary outcome: 1. to investigate whether probiotics can reduce gastrointestinal symptoms caused by nsaids 2. to identify the improvement of arthritis symptoms 3. to examine whether the distribution of the microbiome can be converted into beneficial bacteria by administering probiotics

Eligibility criteria:
inclusion criteria: * patients with axial spa who meet the 2009 asas criteria or osteoarthritis diagnosed by hand or foot x-rays exclusion criteria: * history of taking nsaids or antibiotics within the last month * those who have been taking probiotics, steroids, or immunosuppressants for a long time * abdominal surgical history (exception: appendectomy, cholecystectomy) * history of gastrointestinal malignant disease * abnormal findings requiring drug treatment or surgery in upper gastrointestinal endoscopy (e.g., digestive cancer, acute peptic ulcer, etc.) * hemorrhagic disease * anemia with hemoglobin less than 10 g/dl * past nsaids drug side effects (allergy)
quilt-2.014: gemcitabine and amg 479 in metastatic adenocarcinoma of the pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy

Summary: amg 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (igf-1r). signaling through igf-1r plays an important role in the regulation of cell growth and survival. the primary purpose of the study is to determine if amg 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine.


Eligibility criteria:
inclusion criteria: * untreated metastatic adenocarcinoma of the pancreas * adequate hematologic, renal and liver function * eastern cooperative oncology group (ecog) 0 or 1 exclusion criteria: * prior chemotherapy or radiotherapy for pancreatic cancer * central nervous system metastases * external biliary drain

Keywords: pancreas gemcitabine metastatic jaundice
the bioavailability of rifampicin in (fdcs) widely used in south africa to treat drug-susceptible (tb)

Conditions: Tuberculosis

Summary: 3-way cross-over single dose design evaluating bioavailability of 2 rifampicin-containing fdcs vs a single drug comparator in healthy volunteers

in this study the 4- and 2-drug fdcs (for intensive and continuation phases respectively) widely used within the south african treatment program will be evaluated in a comparative bioavailability study against a single drug rifampicin product registered by the south african medicines control council. a three-way, single dose, cross-over study will be conducted in 24 healthy volunteers

Eligibility criteria:
inclusion * you need to be between the ages of 18-55 years * have a body mass index (bmi) of 19-30 kg/m2 * weigh 45 kg or more * be a non-smoker * be found to be in normal health on history and examination * to have normal blood and urine test results * if you are a woman of child-bearing age, you need to be prepared to not have sexual intercourse, or use a safe form of contraception, until the end of the study exclusion * you are unable to fully understand and comply with the study procedures, requirements and time commitments. * are currently enrolled in any other study evaluating drugs, biologics or devices * you have tb, or have had tb before * you abuse or have abused drugs or alcohol * you have, or have had, drug allergy, severe asthma, or active or recurrent allergic disease * you are pregnant
study of asp7374, cell-culture-derived influenza vaccine

Conditions: Influenza; Vaccine

Summary: the purpose of this study is to compare immunogenicity and safety of asp7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (tiv) in adults ≥20 and \<65 years.


Eligibility criteria:
inclusion criteria: * healthy or medically stable, as judged on the basis of history and concurrent diseases. * subject understands procedure of the protocol and is willing to comply with the protocol. * written informed consent has been obtained. exclusion criteria: * scheduled to receive another vaccine during the study. * received influenza ha vaccine within 180 days prior to screening. * received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine. * diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome. * received one of the following medications or treatment prior to vaccination with the study vaccine. * received one of the following medications or treatment prior to vaccination with the study vaccine: interferon formulation, drugs which affect the immune system, corticosteroids, g-csf, m-csf, human immunoglobulin products, blood products, blood transfusion * history of anaphylactic shock or an allergic reaction such as generalized eruption due to food (including chicken, poultry, foodstuffs derived from chicken, et al.) or drug (including vaccines) allergies, fever ≥39.0°c within 2 days after the previous vaccination (influenza vaccine and others) * history of seizures, except for febrile seizures in childhood

Keywords: asp7374 approved egg-derived vaccine prevention of seasonal influenza
a study of ro5083945 in combination with chemotherapy versus chemotherapy alone in patients with advanced or recurrent non-small cell lung cancer

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Summary: this open label, 2-part study will evaluate the safety and efficacy of ro5083945 in combination with standard chemotherapy in patients with advanced or recurrent non-small cell lung cancer who have not received prior chemotherapy. in part 1 patients will receive ro5083945 intravenously and standard chemotherapy (cisplatin plus either gemcitabine or pemetrexed) for up to 6 cycles of 3 weeks and then ro5083945 until disease progression. in part 2 patients will be randomized to receive either ro5083945 in combination with standard chemotherapy or chemotherapy alone for up to 6 cycles. in the absence of disease progression, patients receiving ro503945 can continue treatment with ro5083945 as monotherapy.


Eligibility criteria:
inclusion criteria: * adult patients, \>/=18 years of age * advanced (iiib), metastatic (iv) or recurrent non-small cell lung cancer * at least 1 measurable disease lesion as per recist criteria * confirmed presence of egfr in tumor tissue * ecog performance status 0-1 * adequate hematological, renal and liver function exclusion criteria: * prior chemotherapy or treatment with another systemic anti-cancer agent * radiotherapy within the last 4 weeks, except for limited field palliative radiotherapy for bone pain relief * symptomatic or active cns metastases * recent history of poorly controlled hypertension (systolic \>180mmhg or diastolic \>100mmhg) * requirement for steroids \> 40 mg prednisolone
health condition of cannabis consumers in the canadian population

Conditions: Cannabis Use; Old Age; Health Risk

Summary: this study evaluates the health condition and its evolution with time of cannabis consumers in the canadian population.

in canada, legalization of recreational use is likely to have decreased the perception of risks associated with cannabis use, and means that the reported adverse effects of cannabis are not so important, suggesting that cannabis may be useful for their illness as an alternative or complementary therapeutic. more canadian physicians prescribed cannabis for their patients. both recreational and medical use of cannabis increase and will continue to grow up in the next coming years. regardless, the typology of cannabis use, more information on the health condition of cannabis consumers may be helpful for the medical prescription of cannabis, in particular in older adults who are more at risk of side effects.

Eligibility criteria:
inclusion criteria: * living in canada the last 20 years * being 60 years and over * being consumer of cannabis exclusion criteria: * living outside canada the last 20 years * have never consumed cannabis
18f-fapi pet in the diagnosis of liver fibrosis

Conditions: Liver Fibrosis; FAP; Positron Emission Tomography

Summary: it is an open label observation clinical trial, all participants are chronic liver disease. the investigators deem to make a novel evaluate criteria to hepatic fibrosis. the point of the clinical trial is to evaluate the novel biomaker 18f-fapi-04 by pet-ct scan in the evaluation of the hepatic fibrosis.

participants are with clinically confirmed chronic liver disease,including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, nonalcoholic fatty liver disease, alcoholic hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and congestive hepatopathy etc. participants are without liver tumor and other liver disease besides liver fibrosis participants has no history of malignant tumors participants agree to performe fapi pet and liver biopsy

Eligibility criteria:
inclusion criteria: * clinically confirmed chronic liver disease,including chronic viral hepatitis, autoimmune hepatitis, liver disease after liver transplantation, nonalcoholic fatty liver disease, alcoholic hepatitis, primary biliary cholangitis, primary sclerosing cholangitis and congestive hepatopathy etc. * without liver tumor and other liver disease besides liver fibrosis * no history of malignant tumors * agree to performe fapi pet and liver biopsy exclusion criteria: * pregnancy * with anti-hepatic fibrosis treatment in 6 months * with contraindications to percutaneous liver biopsy,for such as uncooperative patient, severe coagulopathy, extrahepatic biliary obstruction,etc.
taxotere®, followed by myocet® and cyclophosphamide first line treatment in her2 neg breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine how many pathological complete responses are achieved in patients treated with taxotere® (t) followed by myocet® (m)and cyclophosphamide (mc) first line treatment in her2 negative brest cancer patients.

phase ii, open, not randomized clinical trial, to evaluate the sequential taxotere®, followed by myocet® and cyclophosphamide first line treatment in her2 negative breast cancer patients. the purpose of this study is to determine how many pathological complete responses are achieved in patients treated with taxotere® (t) followed by myocet® (m)and cyclophosphamide (mc) first line treatment in her2 negative brest cancer patients.

Eligibility criteria:
inclusion criteria: * brest adenocarcinoma stages ii/iii * female * informed consent signed * her2 negative * age\>18 years old * ecog \< 1 * proper organic function regarding the following criteria: 1. anc \> 2,0 x 109l, platelets \> 100 x 109l and hemoglobin \> 10g/dl (transfusion is allowed) 2. hepatic function: i.bilirubin \ 1.5 x unl and alkaline phosphatase \> 2.5 x unl will not be selected for the study c.renal function: creatinine \ 60 ml/min d.normal cardiac function, confirmed with fevi \>50% and electrocardiogram. * patients should be available for treatment and follow up and must be treated in investigator or co-investigator site * negative pregnancy test(performed 7 days before treatment) exclusion criteria: * previous treatment for breast cancer (ct, rt, it, ht) * stages iiib, iiic or iv or invasive bilateral breast cancer * previous neoplasias treated with anthracyclines or taxanes (paclitaxel or docetaxel) * pregnant or breastfeeding females * neurotoxicity grade 2 * fev≤50% or any cardiac disease in which anthracyclines are contraindicated * other severe diseases regarding investigator criteria * any neurological or psychiatric pathology * previous neoplasia different from breast cancer except: 1. skin cancer(no melanoma) 2. in situ cervix carcinoma 3. ipsilateral in situ ductal carcinoma 4. in situ lobular in situ carcinoma 5. any other carcinoma without evidence disease in last 10 years * treatment chronic with corticoids (except patients starting 6 months before inclusion with low dosages (\* 20 mg methylprednisolone or equivalent) * concomitant treatment with hormone ovarian replacement therapy * contraindication for corticoids * concomitant treatment with another investigational drugs * included in another clinical trial with any drug in 30 days before inclusion study * concomitant treatment with another anticancer therapy * male patients * hypersensibility to any study drug or components

Keywords: breast cancer patients her2 negative pathological responses
comparative effectiveness of oral anticoagulants

Conditions: Atrial Fibrillation

Summary: this cohort study plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.


Eligibility criteria:
inclusion criteria: * a recorded diagnosis of atrial fibrillation (af). * initiation of anticoagulant medication (dabigatran or warfarin). * at least 18 years of age on the date of anticoagulant initiation cha2ds2-vasc-score \>=1 exclusion criteria: * patients with missing or ambiguous age or sex information * patients with documented evidence of valvular disease * patients with less than 12 months enrolment in the unitedhealth research database preceding the date of anticoagulant initiation * patients with prior use of any oral anticoagulant
evaluation of an asynchronous remote communities approach to behavioral activation for depressed adolescents

Conditions: Depression; Adolescent Behavior

Summary: the goal of this clinical trial is to learn if a digital health intervention, called "activateen," improves depression treatment for teenagers with depression. the investigators also want to know if activateen is easy to use for both teenagers and mental health clinicians who help deliver treatment through activateen. all teenagers in the study will receive an individual depression therapy called behavioral activation or "ba" and about half will also use activateen. the main questions this trial aims to answer are: * does activateen improve depression treatment for teenagers? * do teenagers and clinicians find activateen to be acceptable? researchers will compare teenagers using activateen along with ba to teenagers who are only doing ba to see the effects of activateen. participants in the study will: * fill out surveys online several times during the study, which lasts about 6 months * receive individual ba therapy


Eligibility criteria:
inclusion criteria: * age 13 - 19 * referred for mdd treatment * clinically assessed diagnosis of current mdd based on caregiver or patient report or a phq-8 total of 8 or greater (moderate mdd) * mdd clinically determined to be the primary diagnosis * english-speaking * access to a smartphone device exclusion criteria: * developmental disability (e.g., intellectual disability, autism spectrum disorder) * severe psychiatric comorbidity (e.g., active suicidality requiring higher level of care; psychosis or substance use, bipolar, or conduct disorder) * previously completed a full course of evidence based psychosocial intervention for depression

Keywords: depression adolescence asynchronous remote community behavioral activation digital health
effects of different aerobic exercise programs with nutritional interventions in hypertensive and overweight people

Conditions: Hypertension; Overweight; Sedentary

Summary: obesity and arterial hypertension (htn) frequently coexist in the same patient. moreover, the concept that obesity and htn can be additive in terms of cardiovascular rist is widely accepted. yet, clinical decision-making in obese patients is complicated by a surprising lack of evidence on the relative importance of obesity and htn treatment and its efficacy and safety. lifestyle interventions are the mainstay of obesity management programs and are also advocated in the prevention and treatment of htn. physical exercise and diet are recommended to prevent and control obesity and htn. aerobic exercise is firmly established as an effective measure for lowering blood pressure and reducing cardiovascular risk. however, there is no agreement about the optimal dose of frequency, intensity, duration and type of exercise. therefore, the aims of the study are: 1) to assess the changes in selected parameters of blood pressure, cardiorespiratory fitness, body composition and biological markers brought about by a period of 16-week of different aerobic exercise programs with hypocaloric diet for overweight or obesity and primary hypertensive adults, and 2) to examine the effect of six months detraining subsequent to intervention. secondary objectives are to examine the additional effect of the intervention on physical activity behavior and health-related quality of life.

methodology: participants will perform a ramp incremental cardiopulmonary exercise bike test before, after 16-week of follow-up, and after 6-month detraining period (with no intervention only recommendations). after inclusion criteria they will be randomized to four parallel groups: 1) control group with only hypocaloric diet intervention and lifestyle recommendations; 2) moderate (hr values between vt1 and vt2 or 50-75% of hr reserve) continuous exercise and high volume (from 20 to 45min) group and hypocaloric diet intervention; 3) high intensity (hr values up to vt2 to peak intensity or ≥76% to \<100 % of hr reserve) interval training and high-volume (from 20 to 45min) group alternating high and moderate intensities at different protocols and hypocaloric diet intervention; and 4) high-intensity interval training and low-volume (20min) group alternating high and moderate intensities at different protocolsand hypocaloric diet intervention.

Eligibility criteria:
inclusion criteria: * older than 18yr old and less than 70yr old * overweight (bmi \>25) * primary hypertension * low-moderate cardiovascular risk * not diet treatment * sedentary behavior * availability to exercise two days a week. exclusion criteria: * secondary hypertension * pulmonary disorder * neurological deficit * physical incapacity to exercise * to exercise frequently * pregnancy or breastfeeding * left ventricular hypertrophy * more than three cardiovascular risk factors

Keywords: cardiovascular risk, obesity, interval training, diet